Literature DB >> 24221605

Characteristics of invasive pneumococcal disease in hospitalized children in Austria.

Maria Paulke-Korinek1, Herwig Kollaritsch, Michael Kundi, Birgit Schmidle-Loss, Ines Zwazl, Brigitte Laaber, Karin Lakovits, Andreas Vecsei, Ursula Wiedermann, Heinz Burgmann.   

Abstract

UNLABELLED: In a prospective surveillance study covering all pediatric wards in Austria, 308 cases of invasive pneumococcal disease (IPD) were reported in hospitalized children <5 years of age between 2002 and 2012. Incidence was 7.1 per 100,000 per year for IPD with a case fatality rate of 3 %, and 1.9 per 100,000 per year for pneumococcal meningitis with a case fatality rate of 9 %. At hospital discharge, 17 % of the children were not fully recovered and suffered from problems such as hearing or motor deficits. Persistent sequelae 6 months after hospital discharge were present in 13 % of the children, a finding that emphasizes the seriousness of IPD. From 2007 onwards, we observed a shift of pneumococcal serotypes from those covered by the heptavalent vaccine to serotypes consequently added to 10- and 13-valent vaccines, particularly regarding serotype 19A. Among antimicrobial resistances detected, macrolide resistance was predominant; however, between 2002 and 2012, we saw an overall decrease of resistance rates.
CONCLUSION: Considering this change of serotypes and the high rate of permanent sequelae after IPD, our data show the importance of pediatric pneumococcal vaccination and the relevance of continuous monitoring of circulating serotypes. By the end of 2012, which was the first year of universal mass vaccination against pneumococcal disease in Austria, no change in the incidence of invasive pneumococcal disease was observed yet.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24221605     DOI: 10.1007/s00431-013-2193-2

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  19 in total

1.  Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children.

Authors:  Mark van der Linden; Susanne Weiß; Gerhard Falkenhorst; Annette Siedler; Matthias Imöhl; Rüdiger von Kries
Journal:  Vaccine       Date:  2012-07-04       Impact factor: 3.641

2.  National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases.

Authors:  P Rendi-Wagner; M Paulke-Korinek; M Kundi; H Burgmann; A Georgopoulos; A Vécsei; H Kollaritsch
Journal:  Vaccine       Date:  2009-05-03       Impact factor: 3.641

3.  Decline in early childhood respiratory tract infections in the Norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination.

Authors:  Maria C Magnus; Didrik F Vestrheim; Wenche Nystad; Siri Eldevik Håberg; Hein Stigum; Stephanie J London; Marianne A R Bergsaker; Dominique A Caugant; Ingeborg S Aaberge; Per Nafstad
Journal:  Pediatr Infect Dis J       Date:  2012-09       Impact factor: 2.129

4.  Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.

Authors:  Helene Ingels; Jeppe Rasmussen; Peter Henrik Andersen; Zitta B Harboe; Steffen Glismann; Helle Konradsen; Steen Hoffmann; Palle Valentiner-Branth; Lotte Lambertsen
Journal:  Vaccine       Date:  2012-04-11       Impact factor: 3.641

5.  Community‐acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real‐time polymerase chain reaction using blood samples.

Authors:  Massimo Resti; Maria Moriondo; Martina Cortimiglia; Giuseppe Indolfi; Clementina Canessa; Laura Becciolini; Elisa Bartolini; Fernando Maria de Benedictis; Maurizio de Martino; Chiara Azzari
Journal:  Clin Infect Dis       Date:  2010-11-01       Impact factor: 9.079

6.  American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis.

Authors: 
Journal:  Pediatrics       Date:  2000-08       Impact factor: 7.124

7.  Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.

Authors:  Moe H Kyaw; Ruth Lynfield; William Schaffner; Allen S Craig; James Hadler; Arthur Reingold; Ann R Thomas; Lee H Harrison; Nancy M Bennett; Monica M Farley; Richard R Facklam; James H Jorgensen; John Besser; Elizabeth R Zell; Anne Schuchat; Cynthia G Whitney
Journal:  N Engl J Med       Date:  2006-04-06       Impact factor: 91.245

8.  Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States.

Authors:  Jennifer B Rosen; Ann R Thomas; Catherine A Lexau; Art Reingold; Jim L Hadler; Lee H Harrison; Nancy M Bennett; William Schaffner; Monica M Farley; Bernard W Beall; Matt R Moore
Journal:  Clin Infect Dis       Date:  2011-07-15       Impact factor: 9.079

9.  Dynamics of pneumococcal nasopharyngeal carriage in healthy children attending a day care center in northern Spain. Influence of detection techniques on the results.

Authors:  María Ercibengoa; Nerea Arostegi; José M Marimón; Marta Alonso; Emilio Pérez-Trallero
Journal:  BMC Infect Dis       Date:  2012-03-22       Impact factor: 3.090

10.  Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England.

Authors:  K E Chapman; D Wilson; R Gorton
Journal:  Epidemiol Infect       Date:  2012-05-08       Impact factor: 4.434

View more
  4 in total

1.  Clinical characteristics and serotype distribution of invasive pneumococcal disease in pediatric patients from Beijing, China.

Authors:  Yan Xu; Qing Wang; Kaihu Yao; Fang Dong; Wenqi Song; Gang Liu; Baoping Xu; Wei Shi; Yue Li; Kechun Li; Yingchao Liu; Suyun Qian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-03-31       Impact factor: 3.267

2.  Clinical features and outcomes of invasive pneumococcal disease in a pediatric intensive care unit.

Authors:  Hsiang-Ju Hsiao; Chang-Teng Wu; Jing-Long Huang; Cheng-Hsun Chiu; Yhu-Chering Huang; Jainn-Jim Lin; I-Anne Huang; Oi-Wa Chan; I-Jun Chou; Shao-Hsuan Hsia
Journal:  BMC Pediatr       Date:  2015-07-17       Impact factor: 2.125

Review 3.  Pneumococcal serotype evolution in Western Europe.

Authors:  Myint Tin Tin Htar; Dina Christopoulou; Heinz-Josef Schmitt
Journal:  BMC Infect Dis       Date:  2015-10-14       Impact factor: 3.090

4.  Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program.

Authors:  Lukas Richter; Daniela Schmid; Elisabeth Eva Kanitz; Ines Zwazl; Eva Pöllabauer; Joanna Jasinska; Heinz Burgmann; Michael Kundi; Ursula Wiedermann
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.